Resolution of a clinical AmpliChip CYP450 Test™ no call: Discovery and characterization of novel CYP2D6*1 haplotypes

Pharmacogenomics

Volumn 15, Issue 9, 2014, Pages 1175-1184

  Gaedigk, Andrea ^a,b   Garcia Ribera, Carles ^c   Jeong, Hye Eun ^d   Shin, Jae Gook ^d   Hernandez Sanchez, Juanjo T ^e  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d Inje University College of Medicine   (South Korea)

^e Laboratorio de Referencia de Catalunya   (Spain)

Author keywords

AmpliChip CYP450 Test ; CYP2D6; CYP2D6*10; cytochrome CYP450; genotyping; pharmacogenetics

Indexed keywords

AMOXICILLIN; CLAVULANIC ACID; CYTOCHROME P450 2D6; DIAZEPAM; FOSFOMYCIN; HALOPERIDOL; RISPERIDONE; SERTRALINE; SIMVASTATIN; VALSARTAN;

AGED; ALLELE; ARTICLE; CASE REPORT; CHINESE; COMPUTER ASSISTED TOMOGRAPHY; COPY NUMBER VARIATION; CYP2D6 GENE; DRUG WITHDRAWAL; DSM-IV-TR; FEMALE; FOLLOW UP; GENE LOCUS; GENE SEQUENCE; GENOTYPING TECHNIQUE; HALLUCINATION; HAPLOTYPE; HUMAN; MEDICAL HISTORY; NUCLEOTIDE SEQUENCE; PSYCHOSIS; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN; URINARY TRACT INFECTION; VASCULAR DISEASE; VERY ELDERLY; ASIAN CONTINENTAL ANCESTRY GROUP; GENETICS; PHARMACOGENETICS; PROCEDURES;

AGED, 80 AND OVER; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2D6; DNA COPY NUMBER VARIATIONS; FEMALE; HAPLOTYPES; HUMANS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84906549317     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.94     Document Type: Article

References (44)

1. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin. Pharmacokinet. 48(11), 689-723 (2009).
2. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part II. Clin. Pharmacokinet. 48(12), 761-804 (2009).
3. The Human Cytochrome P450 (CYP) Allele Nomenclature database (2014). www.cypalleles.ki.se
4. Gaedigk A. Complexities of CYP2D6 gene analysis and interpretation. Int. Rev. Psychiatry. 25(5), 534-553 (2013).
5. Hicks JK, Swen JJ, Gaedigk A. Challenges in CYP2D6 phenotype assignment from genotype data: A critical assessment and call for standardization. Curr. Drug Metab. 15(2), 218-232 (2014).
6. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: Overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedeberg's Arch. Pharmacol. 369, 23-37 (2004).
7. Gaedigk A, Leeder JS. CYP2D6 and pharmacogenomics: Where does future research need to focus? Part 1: Technical aspects. Pharmacogenomics 15(4), 407-410 (2014).
8. Leeder JS, Gaedigk A. CYP2D6 and pharmacogenomics: Where does future research need to focus? Part 2: Clinical aspects. Pharmacogenomics 15(8), 1055-1058 (2014).
9. Crews KR, Gaedigk A, Dunnenberger HM et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin. Pharmacol. Ther. 95(4), 376-382 (2014).
10. Hicks JK, Swen JJ, Thorn CF et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin. Pharmacol. Ther. 93(5), 402-408 (2013).
11. Swen JJ, Nijenhuis M, De Boer A et al. Pharmacogenetics: From bench to byte-An update of guidelines. Clin. Pharmacol. Ther. 89(5), 662-673 (2011).
12. National Center for Biotechnology Information (NCBI) Genetic Testing Registry (GTR) (2014). www.ncbi.nlm.nih.gov/gtr/tests/?Term=cyp2d6
13. Pharmacogenomics Knowledge Base (PharmGKB) genetics tests (2014). www.pharmgkb.org/views/viewGeneticTests.action
14. Amplichip. AmpliChip CYP450 Test, CE-IVD, package insert. Roche Molecular Systems Inc., NJ, USA (2009).
15. Gaedigk A, Hernandez J, Garcia-Solaesa V, Sanchez S, Isidoro-Garcia M. Detection and characterization of the CYP2D6 9x2 gene duplication in two Spanish populations: Resolution of AmpliChip CYP450 test no-calls. Pharmacogenomics 12(11), 1617-1622 (2011).
16. Gaedigk A, Isidoro-Garcia M, Pearce RE et al. Discovery of the nonfunctional CYP2D6 31 allele in Spanish, Puerto Rican, and US Hispanic populations. Eur. J. Clin. Pharmacol. 66(9), 859-864 (2010).
17. Gaedigk A, Riffel AK, Berrocal BG, Solaesa VG, Davila I, Isidoro-Garcia M. Characterization of a complex CYP2D6 genotype that caused an AmpliChip CYP450 Test̊ no-call in the clinical setting. Clin. Chem. Lab. Med. 52(6), 799-807 (2014).
18. Gaedigk A, Ndjountche L, Divakaran K et al. Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: Characterization of gene duplication events. Clin. Pharmacol. Ther. 81(2), 242-251 (2007).
19. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83(2), 234-242 (2008).
20. Gaedigk A, Montane Jaime LK, Bertino JS Jr. et al. Identification of Novel CYP2D7-2D6 hybrids: Non-functional and functional variants. Front. Pharmacol. 1, 121 (2010).
21. Gaedigk A, Twist GP, Leeder JS. CYP2D6, SULT1A1 and UGT2B17 copy number variation: Quantitative detection by multiplex PCR. Pharmacogenomics 13(1), 91-111 (2012).
22. Gaedigk A, Fuhr U, Johnson C, Berard LA, Bradford D, Leeder JS. CYP2D7-2D6 hybrid tandems: Identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction. Pharmacogenomics 11(1), 43-53 (2010).
23. Sim SC, Daly AK, Gaedigk A. CYP2D6 update: Revised nomenclature for CYP2D7/2D6 hybrid genes. Pharmacogenet. Genomics 22(9), 692-694 (2012
24. Lee SJ, Lee SS, Jung HJ et al. Discovery of novel functional variants and extensive evaluation of CYP2D6 genetic polymorphisms in Koreans. Drug. Metab. Dispos. 37(7), 1464-1470 (2009).
25. Broad Institute Haploview. www.broad.mit.edu/mpg/haploview
26. Lee SS, Cha EY, Jung HJ et al. Genetic polymorphism of hepatocyte nuclear factor-4alpha influences human cytochrome P450 2D6 activity. Hepatology 48(2), 635-645 (2008).
27. Ryu JY, Song IS, Sunwoo YE et al. Development of the "Inje cocktail" for high-Throughput evaluation of five human cytochrome P450 isoforms in vivo. Clin. Pharmacol. Ther. 82(5), 531-540 (2007).
28. Johansson I, Oscarson M, Yue Q-Y, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the chinese cytochrome P4502D locus: Characterization of variant CYP2D6 genes in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol. 46, 452-459 (1994).
29. Gaedigk A, Bradford LD, Alander SW, Leeder JS. CYP2D6 36 gene arrangements within the CYP2D6 locus: Association of CYP2D6 36 with poor metabolizer status. Drug Metab. Dispos. 34(4), 563-569 (2006).
30. Wand AP. Transient citalopram-induced auditory hallucinations in a patient with Parkinson's disease and depression. Aust. N. Z. J. Psychiatry 46(2), 178 (2012).
31. Schuld A, Archelos JJ, Friess E. Visual hallucinations and psychotic symptoms during treatment with selective serotonin reuptake inhibitors: Is the sigma receptor involved? J. Clin. Psychopharmacol. 20(5), 579-580 (2000).
32. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 68(1), 29-39 (2000).
33. Lopez-Rodriguez R, Cabaleiro T, Ochoa D et al. Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers. Pharmacogenomics 14(10), 1203-1214 (2013).
34. Llerena A, Berecz R, Penas-Lledo E, Suveges A, Farinas H. Pharmacogenetics of clinical response to risperidone. Pharmacogenomics 14(2), 177-194 (2013).
35. Wei Z, Wang L, Yu T et al. Histamine H4 receptor polymorphism: A potential predictor of risperidone efficacy. J. Clin. Psychopharmacol. 33(2), 221-225 (2013).
36. Wei Z, Wang L, Zhang M et al. A pharmacogenetic study of risperidone on histamine H3 receptor gene (HRH3) in Chinese Han schizophrenia patients. J. Psychopharmacol. 26(6), 813-818 (2012).
37. Gaedigk A, Frank D, Fuhr U. Identification of a novel non-functional CYP2D6 allele, CYP2D6 69, in a Caucasian poor metabolizer individual. Eur. J. Clin. Pharmacol. 65, 97-100 (2009).
38. Von Ahsen N, Tzvetkov M, Karunajeewa HA et al. CYP2D6 and CYP2C19 in Papua New Guinea: High frequency of previously uncharacterized CYP2D6 alleles and heterozygote excess. Int. J. Mol. Epidemiol. Genet. 1(4), 310-319 (2010).
39. Affymetrix DMET plus solution (2014). www.affymetrix.com/catalog/131412/ affy/dmet-plus-solution#1-1
40. Luminex xTAG CYP2D6 kit (2014). www.luminexcorp.com/products/assays/ clinicaldiagnostics/xtagcyp2d6
41. Dodgen TM, Hochfeld WE, Fickl H et al. Introduction of the AmpliChip CYP450 test to a South African cohort: A platform comparative prospective cohort study. BMC Med. Genet. 14, 20 (2013).
42. Montane Jaime LK, Lalla A, Steimer W, Gaedigk A. Characterization of the CYP2D6 gene locus and metabolic activity in Indo-And Afro-Trinidadians: Discovery of novel allelic variants. Pharmacogenomics 14(3), 261-276 (2013).
43. Qian JC, Xu XM, Hu GX et al. Genetic variations of human CYP2D6 in the Chinese Han population. Pharmacogenomics 14(14), 1731-1743 (2013).
44. Sim SC, Ingelman-Sundberg M. Update on Allele Nomenclature for Human Cytochromes P450 and the Human Cytochrome P450 Allele (CYP-Allele) Nomenclature Database. Methods. Mol. Biol. 987, 251-259 (2013